Featured Press Releases
ICER Publishes Evidence Report on Therapies for Multiple Myeloma
The evidence suggests CAR-Ts ide-cel and cilta-cel both have the potential to help patients live substantially longer with manageable side effects, although ide-cel’s recently announced price would still require at least a 37% discount to reach ICER’s recommended health-benefit price benchmark. The evidence also suggests belantamab appears to be equivalent or slightly superior to alternative […]
04/05/2021ICER Analytics™ Launched to Accelerate the Real-World Application of ICER Reports, Helping Payers, the Life Science Industry, and Health Care Policy Makers Move From Insight to Action
ICER formally launched ICER Analytics™, a new cloud-based platform that will revolutionize the ability of payers, life science companies, patient groups, and others to develop formularies, negotiate drug prices.
11/30/2020In Landmark International Program, HTA Agencies Around the World Access ICER’s Customizable COVID-19 Cost-Effectiveness Model
Leveraging ICER’s new cloud-based Interactive Modeler platform, Quebec’s HTA agency has used the COVID-19 model to inform Ministerial recommendations on remdesivir; other HTA agencies and research groups in the United Kingdom, Australia, Canada and South Africa plan to access the model.
10/09/2020